×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| SUVEN LIFE SCIENCES LTD. | 24.56 | -147.79 | 18.67 | -0.68 | 5,147 | |
| SEQUENT SCIENTIFIC LTD. | 525.5 | 33.7 | 410.7 | 0.13 | 4607 | 153.0 |
| Dishman Carbogen Amcis Limited | 1002.8 | 26.7 | 628.6 | 0.17 | 4418 | 37.2 |
Suven Life Sciences Ltd., with Security Code 530239, is a leading player in the Healthcare Research- Analytics & Technology industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.6 | 3.8 | 3.1 | 2.5 | 2.4 | 1.0 | 2.6 | 1.6 | 1.5 | 1.9 |
| Expenses | 8.7 | 10.6 | 11.1 | 11.6 | 9.3 | 11.1 | 16.2 | 14.9 | 16.4 | 15.9 |
| Operating Profit | -6.1 | -6.8 | -8.1 | -9.2 | -6.9 | -10.1 | -13.6 | -13.3 | -14.9 | -14.0 |
| OPM % | -234.62% | -178.96% | -263.89% | -375.28% | -288.05% | -1002.78% | -529.97% | -826.02% | -1014.72% | -749.81% |
| Other Income | 5.6 | 5.6 | 12.6 | 6.1 | 4.3 | 3.9 | 4.0 | 1.6 | 1.2 | 0.6 |
| Interest | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Depreciation | 1.7 | 1.7 | 1.7 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.3 | 1.4 |
| Profit before tax | -2.3 | -2.9 | -4.7 | -4.8 | -4.1 | -7.7 | -11.1 | -13.3 | -15.0 | -14.8 |
| Tax % | 0% | 0% | 0% | 0% | -24.3% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -2.2 | -2.9 | 2.8 | -4.8 | -3.1 | -7.7 | -11.1 | -13.3 | -15.1 | -14.8 |
| EPS in Rs | -0.05 | -0.13 | 0.13 | -0.22 | -0.14 | -0.35 | -0.51 | -0.61 | 0 | -0.68 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.0 | 2.6 | 3.8 | 3.1 | 2.5 | 2.4 | 1.0 | 2.6 | 1.6 | 1.5 |
| Expenses | 54.6 | 34.1 | 31.8 | 26.6 | 48.6 | 32.7 | 31.5 | 54.8 | 40.8 | 45.3 |
| Operating Profit | -51.6 | -31.5 | -28.0 | -23.5 | -46.2 | -30.3 | -30.5 | -52.2 | -39.2 | -43.8 |
| OPM % | -1718.39% | -1207.24% | -737.79% | -768.3% | -1884.62% | -1269.94% | -3035.69% | -2029.07% | -2435.09% | -2984.73% |
| Other Income | 2.2 | 5.6 | 5.6 | 12.6 | 6.1 | 4.3 | 4.0 | 4.0 | 1.6 | 1.2 |
| Interest | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Depreciation | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.3 |
| Profit before tax | -51.1 | -27.6 | -24.1 | -20.1 | -41.8 | -27.5 | -28.0 | -49.6 | -39.1 | -43.9 |
| Tax % | 0% | 0% | 0% | 0% | 0% | -3.6% | 0% | 0% | 0% | 0% |
| Net Profit | -51.1 | -27.6 | -24.1 | -12.7 | -41.8 | -26.5 | -28.0 | -49.6 | -39.1 | -43.9 |
| EPS in Rs | -2.9 | -1.17 | -1.1 | -0.58 | -1.92 | -1.22 | -1.29 | -2.27 | -1.79 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -35% |
| 5 Years: | -12% |
| 3 Years: | -17% |
| TTM: | -43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | -6% |
| TTM: | -135% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 46% |
| 3 Years: | 44% |
| 1 Year: | 119% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -35% |
| 5 Years: | -12% |
| 3 Years: | -17% |
| TTM: | -43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -21% |
| 3 Years: | -10% |
| TTM: | -37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 46% |
| 3 Years: | 44% |
| 1 Year: | 119% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|